The Combined Effects of Cannabis, Methamphetamine, and HIV on Neurocognition.
Jeffrey M Rogers, Jennifer E Iudicello, Maria Cecilia G Marcondes...
https://pubmed.ncbi.nlm.nih.gov/36992383/Actively Recruiting
Led by Elazığ Mental Health and Diseases Hospital · Updated on 2026-09-10
90
Participants Needed
2
Research Sites
10 weeks
Total Duration
Researchers are studying psychiatric symptom severity in adult males diagnosed with methamphetamine-induced psychotic disorder MP, comparing those with and without lifetime cannabis use LCU. The study aims to understand whether LCU affects symptom progression and to identify environmental, individual, and family factors linked to psychiatric symptoms in these participants. This prospective cohort study includes hospitalized males at a mental health hospital who meet DSM-5-TR criteria for MP. Participants are divided into two groups based on cannabis use history one with MP plus LCU, defined as using cannabis at least three times in the past 30 days or more than 40 times in the past year, and the other with MP without any lifetime cannabis use. No treatments are assigned by the study. Participants complete baseline sociodemographic and clinical forms and are then assessed weekly for eight weeks during inpatient follow-up using standardized psychiatric and addiction assessment scales. During the eight-week hospitalization, psychiatric symptoms and clinical characteristics are evaluated weekly with tools including the Insight Assessment Scale, Addiction Profile Index Clinical-Practitioner Form, Positive and Negative Syndrome Scale, Global Assessment Scale, and Pittsburgh Sleep Quality Index. Researchers track symptom changes and factors influencing severity, analyzing data after follow-up for scientific publication. The total participation time is eight weeks, with weekly assessments throughout hospitalization.
CONDITIONS
Psychiatric Symptom Characteristics in Methamphetamine-Induced Psychosis With and Without Lifetime Cannabis Use
M
Mehmet Hamdi ÖRÜM, MD, Assoc. Prof., Psychiatrist
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Elazığ Mental Health and Diseases Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 8 weeks
Participants complete baseline questionnaires and are assessed weekly using psychiatric and addiction scales during an eight-week hospital stay.
Weekly visits for 8 weeks
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jeffrey M Rogers, Jennifer E Iudicello, Maria Cecilia G Marcondes...
https://pubmed.ncbi.nlm.nih.gov/36992383/Rebecca McKetin, Amanda L Baker, Sharon Dawe...
https://pubmed.ncbi.nlm.nih.gov/28282630/John E Schulenberg, Alicia C Merline, Lloyd D Johnston...
https://pubmed.ncbi.nlm.nih.gov/16534532/Travis A Wearne, Jennifer L Cornish
https://pubmed.ncbi.nlm.nih.gov/30364176/Dilek Örüm, Mehmet Hamdi Örüm, Yaşar Kapıcı...
https://pubmed.ncbi.nlm.nih.gov/39160490/Kelly E Courtney, Lara A Ray
https://pubmed.ncbi.nlm.nih.gov/25176528/Suzette Glasner-Edwards, Larissa J Mooney
https://pubmed.ncbi.nlm.nih.gov/25373627/Elazığ Mental Health and Diseases Hospital
Lead Sponsor